Official Guidance and Warnings While the Zepbound warning label clearly states that severe stomach problems are a possible serious side effect and recommends against use in patients with existing gastroparesis, it does not explicitly list new stomach paralysis or gastroparesis as potential risks that can be caused by the drug in all patients
If so, defining the molecular trigger(s) that regulates alpha-cell PC1/3 expression has the potential to identify targeting strategies that can switch alpha-cells from being diabetes promoting to diabetes preventing
The company states that interim results from the ongoing phase 1b study assessing multiple ascending doses of GUBamy are expected during the first half of 2025 [117]
Interaction with inflammatory pathways is associated with recovery from exercise-induced inflammation and tissue irritation
GLP-1 medications make it easier to lose weight by curbing appetite, reducing cravings, and slowing stomach emptying
The association can provide the benefit of two highly effective drugs in glycemic control and attenuate adverse events, such as hypoglycemia and weight gain (these benefits will be discussed in detail further in the article)
